Treatment of Drug-Induced Dyskinesia

Introduction to Drug-Induced Dyskinesia

• The primary treatment for drug-induced dyskinesia is to discontinue or reduce the dose of the offending medication, with atypical antipsychotics being the preferred alternative if continued antipsychotic treatment is necessary, as recommended by the American Academy of Sleep Medicine 1

Types of Drug-Induced Dyskinesia

• Tardive dyskinesia (TD) is characterized by athetoid or choreic movements, typically in the orofacial region, according to the American Academy of Child and Adolescent Psychiatry 2
• Tardive dystonia is characterized by slow movements along the body's long axis culminating in spasms, as described by the American Academy of Child and Adolescent Psychiatry 2
• Acute dystonia is marked by sudden spastic contractions of distinct muscle groups, as noted by the American Academy of Child and Adolescent Psychiatry 3
• Akathisia is severe restlessness manifesting as pacing or physical agitation, as defined by the American Academy of Child and Adolescent Psychiatry 3

First-Line Management Approaches

• Discontinue the offending medication if clinically feasible, as recommended by the American Academy of Sleep Medicine and the American Academy of Child and Adolescent Psychiatry 1, 4
• If antipsychotic therapy must continue, switch to an atypical antipsychotic with lower TD risk, as suggested by the American Academy of Child and Adolescent Psychiatry 4, 5
• Consider dose reduction of the current medication, as recommended by the American Academy of Child and Adolescent Psychiatry 6
• Atypical antipsychotics have lower risk of causing extrapyramidal symptoms and TD compared to typical antipsychotics, according to the American Academy of Family Physicians 7

Treatment of Acute Extrapyramidal Symptoms

• Acute dystonia should be treated with anticholinergic medications or antihistamines, as recommended by the American Academy of Child and Adolescent Psychiatry 3
• Akathisia should be managed by lowering the antipsychotic dose if possible, and considering β-blockers or benzodiazepines, as suggested by the American Academy of Child and Adolescent Psychiatry 3

Prevention Strategies

• Use atypical antipsychotics when possible, as they have lower TD risk compared to typical antipsychotics, as recommended by the American Academy of Child and Adolescent Psychiatry 4
• Perform baseline assessment of abnormal movements before starting antipsychotic therapy, and monitor regularly for dyskinesias at least every 3-6 months using the Abnormal Involuntary Movement Scale (AIMS), as suggested by the American Academy of Child and Adolescent Psychiatry 4
• Provide adequate informed consent regarding TD risk when prescribing antipsychotics, as recommended by the American Academy of Child and Adolescent Psychiatry 4

Special Considerations

• Withdrawal dyskinesia may occur with either gradual or sudden cessation of neuroleptic agents but typically resolves over time, as noted by the American Academy of Child and Adolescent Psychiatry 2
• Persistent TD may not resolve even after medication discontinuation, highlighting the importance of prevention, as emphasized by the American Academy of Child and Adolescent Psychiatry 2
• Up to 50% of youth receiving neuroleptics may experience some form of tardive or withdrawal dyskinesia, according to the American Academy of Child and Adolescent Psychiatry 2

Tardive Dyskinesia Diagnosis and Management

Diagnostic Considerations

• Documenting baseline movements before antipsychotic initiation is crucial to avoid mislabeling, as recommended by the American Academy of Child and Adolescent Psychiatry 8, 9

Treatment Options

• Clozapine may be considered for patients with treatment-resistant schizophrenia or when TD develops despite other interventions, according to the American Academy of Child and Adolescent Psychiatry 9

High-Risk Scenarios

• Depot antipsychotics carry inherent risks with long-term neuroleptic exposure and should be used cautiously, as noted by the American Academy of Child and Adolescent Psychiatry 8

Tardive Dyskinesia and Extrapyramidal Symptoms Management

Introduction to EPS and TD

• The American Academy of Child and Adolescent Psychiatry notes that acute Extrapyramidal Symptoms (EPS) occur early in treatment and respond to anticholinergics or dose reduction, while Tardive Dyskinesia (TD) develops after long-term antipsychotic exposure and has no specific treatment other than medication discontinuation or switching to VMAT2 inhibitors 10

Clinical Presentation

• Acute EPS manifest during initial treatment phases with distinct syndromes, including dystonia, parkinsonism, and akathisia, which can occur within days of starting treatment 10, 11
• Dystonia is characterized by sudden spastic muscle contractions, often within days of starting treatment 10, 11
• Parkinsonism is marked by bradykinesia, tremors, and rigidity mimicking Parkinson's disease 10
• Akathisia is severe restlessness with pacing and physical agitation 10

Management of Acute EPS

• The American Academy of Child and Adolescent Psychiatry recommends that dystonia requires immediate treatment with anticholinergic medications or antihistamines, as laryngospasm can be life-threatening 10
• Parkinsonism responds to anticholinergic agents or amantadine 10
• Akathisia management involves lowering the antipsychotic dose if clinically feasible, or trialing β-blockers or benzodiazepines 11

Management of Tardive Dyskinesia

• The management approach for TD is fundamentally different and more limited, with VMAT2 inhibitors being a first-line treatment for moderate-to-severe TD 10, 11
• If antipsychotic treatment must continue, switching to atypical antipsychotics with lower D2 affinity, such as clozapine, is recommended 11

Reversibility and Prognosis

• Acute EPS are reversible with appropriate treatment or dose adjustment 10
• TD may persist indefinitely even after medication discontinuation, making prevention paramount 10, 11

Prevention Strategies

• Using atypical antipsychotics preferentially can help prevent both conditions, as they carry a significantly lower risk than typical antipsychotics 10, 11
• Documenting baseline abnormal movements and monitoring for dyskinesias every 3-6 months can help prevent TD 10, 11

Risk Factors

• Young age, male gender, and high-potency typical antipsychotics are risk factors for acute EPS 10
• Older age, female gender, presence of acute EPS, diabetes mellitus, affective disorders, and higher doses and longer duration of antipsychotic exposure are risk factors for TD 10

Differentiating Akathisia from Tardive Dyskinesia

Nature of the Symptoms

• Akathisia is characterized by a subjective component of inner sense of restlessness, severe tension, and compulsion to move, with semi-voluntary movements such as pacing, inability to sit still, marching in place, crossing/uncrossing legs, and trunk rocking, often misinterpreted as psychotic agitation or anxiety, leading to inappropriate dose increases, as noted by the American Academy of Child and Adolescent Psychiatry 12
• Tardive dyskinesia is characterized by involuntary and rhythmic movements, typically rapid involuntary facial movements including blinking, grimacing, chewing, or tongue movements, primarily affecting the orofacial region, as described by the American Academy of Child and Adolescent Psychiatry 12

Location of Movements

• Tardive dyskinesia primarily affects the orofacial region, though choreiform limb movements can occur, as noted by the American Academy of Child and Adolescent Psychiatry 12

Associated Features

• Akathisia may occur alongside other acute extrapyramidal symptoms, causes severe subjective distress, and is a common reason for medication noncompliance, as reported by the American Academy of Child and Adolescent Psychiatry 12
• Up to 50% of youth receiving neuroleptics may experience some form of tardive or withdrawal dyskinesia, according to the American Academy of Child and Adolescent Psychiatry 12

Response to Treatment

• Akathisia responds to lowering the antipsychotic dose, and β-blockers or benzodiazepines provide relief, while anticholinergic agents are not consistently helpful, as noted by the American Academy of Child and Adolescent Psychiatry 12

Risk Factors

• Young age and male gender are risk factors for akathisia, as reported by the American Academy of Child and Adolescent Psychiatry 12

Practical Assessment Algorithm

• When evaluating a patient on antipsychotics with movement abnormalities, observing location, such as predominantly leg/trunk movements with pacing, suggests akathisia, while orofacial movements suggest tardive dyskinesia, as described by the American Academy of Child and Adolescent Psychiatry 12

Tardive Dyskinesia Causes and Management

Medications Associated with Tardive Dyskinesia

• First-generation antipsychotics, such as haloperidol, chlorpromazine, fluphenazine, and perphenazine, are associated with a high risk of tardive dyskinesia, according to the American Academy of Pediatrics 13
• The American Academy of Pediatrics recommends investigating prior medication exposure, including antipsychotics or antiemetics used in the past, as tardive dyskinesia can persist even after the offending agent is discontinued, particularly in patients with a history of emergency department visits where antipsychotics may have been administered 13

Diagnostic Considerations

• A complete medication history, including any antipsychotics or antiemetics used in the past, is essential to diagnose tardive dyskinesia, as recommended by the American Academy of Neurology, although no specific citation is provided in the text, the first citation is relevant to this point 13

Switching to Lower‑Risk Antipsychotics: Use of Aripiprazole or Cariprazine

Alternative Antipsychotic Options

• In patients who must continue antipsychotic therapy, clinicians should consider switching to aripiprazole or cariprazine as lower‑risk alternatives, especially when prominent negative symptoms are present 14